Acelrx Pharmaceuticals Inc (NASDAQ:ACRX) Sellers Increased Their Shorts By 1.48%

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Corporate Logo

Big Money Sentiment increased to 1.22 in Q2 2018. It has change of 0.15, from 2018Q1’s 1.07. The ratio increased due to AcelRx Pharmaceuticals, Inc. positioning: 7 sold and 11 reduced. 9 funds acquired positions and 13 increased positions. Investors holded 4.27 million in 2018Q1 but now own 4.49 million shares or 5.17% more.
74,236 are owned by Northern. Creative Planning stated it has 0% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Cambridge Advsr has invested 0% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Blackrock holds 0% of its capital in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 673,115 shs. Geode Capital Mngmt Llc holds 250,005 shs or 0% of its capital. Moreover, Burt Wealth has 0% invested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 1,000 shs. Fmr Lc reported 298,644 shs. Jane Street Group Ltd Com holds 12,481 shs or 0% of its capital. Wells Fargo Mn has invested 0% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Invesco Ltd owns 12,865 shs for 0% of their capital. Hrt Limited Liability Co stated it has 0.02% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Manufacturers Life Insurance The has 362 shs for 0% of their capital. Moreover, Art Advsr Ltd Com has 0.01% invested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 40,998 shs. Grp Inc One Trading L P owns 37,393 shs or 0% of their US capital. Citadel Advsrs Limited Com reported 119,363 shs stake.

AcelRx Pharmaceuticals, Inc. had 3 insider sales and 3 insider purchases since September 24, 2018. This’s net activity of $75,982. 28,351 shs valued at $141,755 were sold by Dasu Badri N on Monday, October 15. On Monday, November 19 Palmer Pamela P had bought 16,000 shs worth $49,120. On Thursday, November 15 EDWARDS MARK G bought $58,376 worth of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) or 20,700 shs. On Tuesday, November 13 ASADORIAN RAFFI had bought 5,000 shs worth $15,646.

It was reported an increase on Acelrx Pharmaceuticals Inc (NASDAQ:ACRX)’s shorted shares with 1.48%. In December was announced ACRX’s total 3.25 million shorted shares by FINRA. That’s 1.48% up from 3.21M shares. Acelrx Pharmaceuticals Inc (NASDAQ:ACRX) has 469,100 shares average volume. It’ll cost 7 days for ACRX to recover its previous position.

The stock increased 3.07% or $0.1 during the last trading session, reaching $3.36.AcelRx Pharmaceuticals, Inc. has volume of 1.61M shares. Since December 8, 2017 ACRX has risen 1.54% and is uptrending. The stock underperformed the S&P500 by 14.08%.

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain.The firm is worth $256.68 million. The Company’s lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet, which is in Phase III clinical trial for the treatment of moderate-to-severe acute pain.Currently it has negative earnings. The companyÂ’s late-stage investigational product candidate is Zalviso, a pre-programmed and patient-controlled analgesia device that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Ratings Coverage

In total 5 analysts cover AcelRx Pharmaceuticals (NASDAQ:ACRX). “Buy” rating has 4, “Sell” are 0, while 1 are “Hold”. (NASDAQ:ACRX) has 80% bullish analysts. 6 are the (NASDAQ:ACRX)’s ratings reports on Dec 8, 2018 according to StockzIntelligence Inc. On Monday, October 15 the firm earned “Buy” rating by Jefferies. In Wednesday, October 10 report Ladenburg Thalmann maintained the stock with “Buy” rating.

For more AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) news brought out briefly go to:,,, or The titles are as follows: “AcelRx: A Valuation – Seeking Alpha” brought out on October 31, 2018, “Your Daily Pharma Scoop: AcelRx Briefing Docs Released, Motus GI Up On Data – Seeking Alpha” on October 11, 2018, “AcelRx Pharmaceuticals Gets A Thumbs Up From Advisory Committee – Seeking Alpha” with a publish date: October 16, 2018, “Hopes Are High For AcelRx After Dsuvia Approval – Will Price Follow? – Seeking Alpha” and the last “3 Stocks to Hold for the Next 20 Years – The Motley Fool” with publication date: December 01, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.